🇺🇸 FDA
Patent

US 7723018

Methods of assaying for cell cycle modulators using components of the ubiquitin ligation cascade

granted A61KA61K31/713A61K38/53

Quick answer

US patent 7723018 (Methods of assaying for cell cycle modulators using components of the ubiquitin ligation cascade) held by Rigel Pharmaceuticals, Inc. expires Mon May 20 2030 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Rigel Pharmaceuticals, Inc.
Grant date
Tue May 25 2010 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 20 2030 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
13
CPC classes
A61K, A61K31/713, A61K38/53